Boston University School of Law

Scholarly Commons at Boston University School of Law
Faculty Scholarship
1998

Transgenic Agriculture: Biosafety and International Trade
Michael S. Baram
Boston University School of Law

Calestuous Juma
Sheldon Krimsky
Rufus King

Follow this and additional works at: https://scholarship.law.bu.edu/faculty_scholarship
Part of the Science and Technology Law Commons

Recommended Citation
Michael S. Baram, Calestuous Juma, Sheldon Krimsky & Rufus King, Transgenic Agriculture: Biosafety and
International Trade , in 4 Boston University Journal of Science & Technology Law 156 (1998).
Available at: https://scholarship.law.bu.edu/faculty_scholarship/3247

This Article is brought to you for free and open access by
Scholarly Commons at Boston University School of Law.
It has been accepted for inclusion in Faculty Scholarship
by an authorized administrator of Scholarly Commons at
Boston University School of Law. For more information,
please contact lawlessa@bu.edu.

DATE DOWNLOADED: Tue Aug 30 18:05:35 2022
SOURCE: Content Downloaded from HeinOnline
Citations:
Bluebook 21st ed.
Michael Baram , Calestous Juma, Sheldon Krimsky & Rufus C. King, Transgenic
Agriculture: Biosafety and International Trade, 4 B. U. J. Sci. & TECH. L. 156
(1998).
ALWD 7th ed.
Michael Baram , Calestous Juma, Sheldon Krimsky & Rufus C. King, Transgenic
Agriculture: Biosafety and International Trade, 4 B. U. J. Sci. & Tech. L. 156
(1998).
APA 7th ed.
Baram, M., Juma, C., Krimsky, S., & King, R. C. (1998). Transgenic Agriculture:
Biosafety and International Trade. Boston University Journal of Science & Technology
Law, 4, 156-178.
Chicago 17th ed.
Michael Baram; Calestous Juma; Sheldon Krimsky; Rufus C. King, "Transgenic
Agriculture: Biosafety and International Trade," Boston University Journal of Science
& Technology Law 4 (1998): 156-178
McGill Guide 9th ed.
Michael Baram et al., "Transgenic Agriculture: Biosafety and International Trade"
(1998) 4 B U J Sci & Tech L 156.
AGLC 4th ed.
Michael Baram et al., 'Transgenic Agriculture: Biosafety and International Trade'
(1998) 4 Boston University Journal of Science & Technology Law 156
MLA 9th ed.
Baram, Michael, et al. "Transgenic Agriculture: Biosafety and International Trade."
Boston University Journal of Science & Technology Law, 4, 1998, pp. 156-178.
HeinOnline.
OSCOLA 4th ed.
Michael Baram , Calestous Juma, Sheldon Krimsky & Rufus C. King, 'Transgenic
Agriculture: Biosafety and International Trade' (1998) 4 B U J Sci & Tech L 156
Provided by:
Fineman & Pappas Law Libraries
-- Your use of this HeinOnline PDF indicates your acceptance of HeinOnline's Terms and
Conditions of the license agreement available at
https://heinonline.org/HOL/License
-- The search text of this PDF is generated from uncorrected OCR text.
-- To obtain permission to use this article beyond the scope of your license, please use:
Copyright Information

4 B.U. J. Sci. & TECH. L. 4

April 17, 1997

Boston University
Journal of Science & Technology Law
Symposium
Transgenic Agriculture: Biosafety and International Trade
Michael Baram, Calestous Juma,
Sheldon Krimsky, and Rufus C. King
Table of Contents
Sp eech es ..........................................................................................................................
Mich ael B aram ..................................................................................................
C alestou s Ju m a .............................................................................................
Sheldon K rimsky ............................................................................................
R u fu s C . King ..................................................................................................
D iscu ssion Session ....................................................................................................

[1]
[1]
[101
[141
[281
[34]

Transgenic Agriculture: Biosafety and
International Tradet
Michael Baram, Calestous Juma,
Sheldon Krimsky, and Rufus C. King*
Michael Baram:1

1. We stand at the threshold of a new century that will bring novel methods of
producing foods, industrial materials, pharmaceuticals, and other products
important to society and industry. 2 Today's session will, therefore, address a subject
of great importance: the introduction of genetically modified crops, livestock, microorganisms, and other substances into agriculture and related fields, made possible
by American and foreign corporate biotechnology.
2. But these genetic advances and their potential benefits 3 are not without
controversy. 4 Over the last few years, genetically-modified crops and

© 1998 by the Trustees of Boston University; Boston University Journal of Science &
Technology Law. Cite to this Symposium as 4 B.U. J. SCI. & TECH. L. 4 (1998). Pin cite using the
appropriate paragraph number. For example, cite the first paragraph of this Symposium as 4 B.U.
J. SCI. & TECH. L. 4 para. 1 (1998) (comments of Michael Baram). These proceedings are from the
fourth session of the Biotech Law Symposium held at Boston University School of Law on April 17,
1997. For the proceedings of the other sessions, see 4 B.U. J. SCI. & TECH. L. 1-3 (1998). Editor's
note: To aid the reader, the Journal of Science & Technology Law's staff has provided additional
authority for the speakers' comments, referenced in the attached footnotes.
Editor's note: Four persons originally participated in this Symposium. Because of
unavailability prior to publication, the comments of one person, Mr. Richard Godown of BIO, have
not been included.
I

Michael Baram is a professor of law at Boston University School of Law. He is also the
Director of the Boston University Center for Law and Technology.
2

See Robert J. Frederick & Margaret Egan, Environmentally CompatibleApplications of

Biotechnology, 44 BIOSCIENCE 529, 529 (1994) (discussing uses of biotechnology in bioremediation,
bioleaching, natural plastics, clean fuels, and agriculture).
See Cath Blackledge, Genetic Science Know-How Will Determine Leadership in 21st Century,
PHARMACEUTICAL BUS. NEWS, July 16, 1997, available in LEXIS, Market Library,
PROMT File (discussing statements made by the chairman of Glaxo Wellcome about the future of
the pharmaceutical industry); see also Steve Sternberg, Prospecting or Modern Day Colonialism?
EthicistsExamine Who Profits from Genetic Research, BIOWORLD TODAY, May 8, 1996, available in
1996 WL 9518319.
3

Says Sykes,
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microorganisms have moved from contained laboratories into commerce and the
open environment. 5 Despite testing and other assurances of their safety,6 there are
persistent concerns and some research findings that such products pose threats to
ecosystems and consumer health, and to the sustainable development aspirations of
7
developing nations.
3. Thus, concern about "biosafety" has arisen and poses complex issues in
policy debates in the United States8 and abroad,9 in forums such as the United
Nations ("UN"), the European Community, 6 and various non-governmental
organizations. "
4. After talking with today's speaker and panelists, I see four central issues
for discussion. First, does transgenic agriculture pose foreseeable risks to the
environment and human health? In addressing this issue, we need to consider recent
See Maurizio G. Paoletti & David Pimentel, Genetic Engineeringin Agriculture and the
Environment:Assessing Risks and Benefits, 46 BIOSCIENCE 665, 670-71 (1996) (listing the following
"questionable uses of genetic engineering": the use of growth hormones in dairy cattle, the use of
microbes for pest control, and the release of genetically engineered organisms).
4

See id. at 665, 668 (citing 1993 Group of NationalExperts on Safety in Biotechnology,
ANALYSIS OF FIELD RELEASE EXPERIMENTS (Organization forEuropean Cooperation and
Development, Paris, France) May 14, 1993 & Sept. 1993 update). Paoletti & Pimental also state
that since 1992, more than 2000 genetically engineered plants have been released without any
problem. See id. at 668.
See id. at 665 (explaining that genetic engineering and the use of transgenic species has
reduced the time required to develop new crops and improve farming in developing countries).
6

See Michael Freemantle, U.K. Panel Urges Gene ModificationProtocol, CHEMICAL &
ENGINEERING NEWS, Feb. 5, 1996, at 9 (reporting an independent advisory panel's warning that
new rules are needed to avoid large scale environmental problems).
7

See generally Isaac Rabino, What U.S. ResearchersThink of Regulations and Regulators, 14
BIO/TECH. 147, 147 (1996) (reporting that most U.S. researchers using recombinant DNA "would
prefer a centralized unit to be responsible for regulating biotechnology").
8

See Michael Baram, LMO's: Treasure Chest or Pandora'sBox?, 104 ENVTL. HEALTH PERSP.
704 (1996). LMO's are living modified organisms, a term used interchangably with genetically
modified organisms (GMOs).
9

10

See Brian Kirsop, European Union'sDrive Toward a Single Market is Moving a Set of
EuropeanBiotechnology StandardsNearer Completion, GENETIC ENGINEERING NEWS, Sept. 15,
1997, available in 1997 WL 8970594 (reporting on the European Committee for Standardization's
efforts to form common standards for "biosafety, . . . containment of genetically manipulated
organisms (GMOs), their release and marketing, and protecting the health and safety of workers
using GMOs").
II

See Frederick & Egan, supra note 2, at 534 (listing international organizations that have

established biotechnology regulations).
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developments, such as the release of genetically modified microorganisms to combat
pests and the harvest of genetically modified crops which are entering the food chain
2
and now reach the dinner table.'
5. Second, biosafety in transgenic agriculture raises a number of critical risk
management questions. 13 If transgenic agriculture does present risks, are the risks
manageable? Is risk management convenient and affordable for all nations, or does
it require sophisticated technology and expertise available only to wealthy countries
such as the United States? What steps need to be taken to shape individual and
collaborative efforts to manage risk?
6. Several organizations have enacted guidelines for preventing biosafety
problems. These guidelines address the technology itself, the need for public
education, public involvement, and agricultural training, which raise the third
15
14
important issue. Are the guidances sufficient and will they be followed?
Regulation is not the easy answer from any standpoint. If regulation would be
beneficial, should it be technical and prescriptive, 16 an approach we seem to have
abandoned in addressing other risks? 17 Alternatively, should regulation focus on
performance, with final outcome criteria, and thereby afford more flexibility to the

12

See Paoletti & Pimentel, supra note 4, at 666 (discussing the introduction of new genes into

crops and livestock).
13

See id. at 533-34 (discussing the need for regulation to control the risks associated with

biotechnology and transgenic research); see also Ted Plafker, FirstBiotech Safety Rules Don'tDeter
Chinese Efforts, 266 SCIENCE 966, 966 (1994) (reporting on Chinese releases of transgenic plants
and organisms into the environment).
See generally Environmental Release of Genetically Engineered Organisms: Recasting the
Debate, GENEWATCH (Comm. for Responsible Genetics, Boston, Mass.), Mar.-June 1988, at 1, 2,
reprintedin COUNCIL FOR RESPONSIBLE GENETICS, GENETIC ENGINEERING: UNRESOLVED ISSUES
(1992).
14

15

See Rabino, supra note 8, at 147 (reporting researchers' opinions of various U.S. agencies'

regulatory efforts).
16

See id. at 150 (stating that researchers favor risk assessments of their products instead of

regulation of the processes used to develop the products); see also Paoletti & Pimentel, supra note 4,
at 665 (asserting that U.S. deregulation of transgenic agriculture followed by the release of
genetically engineered organisms into the wild would be a danger).
17

See AGBIOTECH: USDA Simplifies Approval Rules, APPLIED GENETICS NEWS, Sept. 1, 1997,

available in LEXIS, Market Library, PROMT File (reporting amended regulations pertaining to
procedures for obtaining non-regulation status of field tests of genetically engineered plants); see also
Specification of Requirements and Procedures for Genetically Engineered Organisms, 60 Fed. Reg.
43,567, 43,567 (1995) (proposed Aug. 22, 1995) (proposing "to simplify procedures for the
introduction of certain genetically engineered organisms").
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regulated parties? 18 Which institutions should be authorized to manage the risks?19
Should farmers and other members of the private sector be encouraged to selfregulate?20 Should responsibility devolve to nations or to nongovernmental
organizations? 2 1 Overall, what infrastructure is needed to maximize the benefits
22
and minimize the risks of this promising new area of technology?
7. Finally, there is the fourth issue to consider here: in addressing these
technological and regulatory issues, can we also achieve results which are consistent
with principles of free trade? Countries which support multilateral programs to
address the risks of genetically engineered products might reconsider if the
programs and strictures impair their ability to trade. And should trade be premised
on technology transfer to developing nations, in order to develop their capacities and
lessen their dependence on multinational biotech agriculture companies and
western expertise - an issue that is likely to influence which nations support or
reject any binding international agreements and subsequent regulations.
8. We have a most highly-qualified speaker to discuss these complex issues,
Dr. Calestous Juma. Dr. Juma is a distinguished scholar, researcher, and author of
many books and articles on biotechnology, agriculture, and biodiversity, and serves
as Executive Secretary of the United Nations Convention on Biological Diversity
("CBD" or "Convention"). 23 The Convention has been ratified by more than 150
nations, with the United States as one of the few non-ratifying countries. 24 The
ratifying nations are now devoting their energies to establishing a biosafety protocol,

18

See Rabino, supranote 8, at 150 (stating researchers disfavor regulation of process).

19

See id. at 147-50 (discussing industry opinions of current institutional regulations).

20

See Kathryn S. Brown, Life on the Molecular Farm: TransgenicPlantsAre Extending the

Range of Chemical ProductionPossibilitiesin Agriculture, 46 BIOSCIENCE 80, 83 (1996) (discussing
the application of the USDA's easing of regulations for genetically engineered organisms and
criticism that the move places too much responsibility in private hands).
21

See id.

22

See Paoletti & Pimentel, supra note 4, at 671 (concluding that transgenic agriculture has

potential benefits, but without regulation and control, these benefits will be jeopardized).
23

Convention on Biological Diversity, opened for signature June 5, 1992, 31 I.L.M. 818.

24

See PARTICIPATION IN WORLD TREATIES ON THE PROTECTION OF THE ENVIRONMENT: A

COLLECTION OF DATA 268-71 (Maria Clara Maffei et al. eds., 1997) (listing parties to the Convention
on Biological Diversity).

4 B.U. J. Sci. & TECH. L. 4

Transgenic Agriculture

that would be legally binding at the international level. 25 In directing the CBD, Dr.
Juma's responsibilities are to protect global biodiversity and promote sustainable
development. He now has the additional task of presiding over the CBD Working
Group that is developing the biosafety protocol. We are honored to have him here.
9. Our panelists are also leaders in their respective fields. Professor Sheldon
Krimsky is a risk policy analyst and biosafety specialist at Tufts University. He is
also the author of illuminating books and reports on the subject of genetics and
agriculture. 2 6 Rufus King is an attorney for biotechnology companies at the Boston
law firm of Testa, Hurwitz & Thibeault. Richard Godown represents BIO, the trade
27
association of biotechnology companies.
28

Calestous Juma:
10. I am very happy to take this opportunity to share with you some of the
developments that are taking place under the Convention. Before I get into the
issues relating to the international regulation of biotechnology, I would like to spend
a few moments giving you some background about the evolution of the concepts
under the Convention. The United Nations has a long history of involvement with
environmental issues through internal bodies such as the United Nations
Environment Programme ("UNEP"). 2 9 Indeed, the UNEP played a central role in
facilitating the initial working papers and other materials that evolved into the text
of the Convention. 30 In 1992, the United Nations sponsored the Conference on
Environment and Development, known as the Earth Summit, in Rio de Janeiro,
Brazil, to discuss a variety of issues that confront the threats to natural habitats

25

See Convention on Biological Diversity, supra note 23, art. 28, 31 I.L.M. at 834; U.N Expert's

Meeting Recommends Protocol on Genetically Modified Organisms, [1995] 18 Int'l Env't Rep. (BNA)
No. 16, at 599 (Aug. 9, 1995).
26

See, e.g., SHELDON KRIMSKY, BIOTECHNICS AND SOCIETY: THE RISE OF INDUSTRIAL GENETICS

& ROGER P. WRU7EEL, AGRICULTURAL BIOTECHNOLOGY AND THE
ENVIRONMENT: SCIENCE, POLICY, AND SOCIAL ISSUES (1996).
(1991); SHELDON KRIMSKY

27

Editor's note:
Mr. Godown was unavailable prior to this publication, and his remarks have, therefore, been

deleted.
28

Calestous Juma is the Executive Secretary of the Convention on Biological Diversity.

29

See Biosafety Under the Biodiversity Convention (visited Nov. 6, 1997)

<http://www.iisd.calinkages/vo109/0948003e.html> (UNEP is also attempting to develop technical
guidelines for biosafety).
3o

See Convention on Biological Diversity, supra note 23, 31 I.L.M. at 818 microformedon

Readex No. [ST/]DPI/1307] (Dept. of Pub. Info.) (providing a brief history of the international efforts
preceding the CBD's adoption).
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and ecosystems. The Convention, a particularly important element of that
Conference, is designed to look at ecological issues within a larger context.
11. The objectives of the Convention are both simple to express and difficult
to achieve. To quote the Convention itself:
The objectives of this Convention, to be pursued in
accordance with its relevant provisions, are the
conservation of biological diversity, the sustainable use of
its components and the fair and equitable sharing of the
benefit arising out of the utilization of genetic resources,
including by appropriate access to genetic resources and
by appropriate transfer of relevant technologies, taking
into account all rights over those resources and to
31
technologies, and by appropriate funding.
This single sentence embraces a primary concern for three issues which will take
significant effort to reconcile in the real world: conserving the wealth of organisms
and biological differences that exist on earth and intricately work together to make
the planet fruitful and habitable; finding ways to continue to use the earth's
resources in a environmentally sensitive and sustainable way; and determining an
equitable way to share the benefits and control the risks of the technologies and
human activities that exploit these resources.
12. The Earth Summit provided a focused opportunity for gathering nations
to sign the Convention, which was signed by more than five times the minimum
number required to begin future work on binding international agreements in this
area. 32 The parties to the CBD understood its role as an unprecedented initial step
to greater international understanding and cooperation on issues that span the line
between species and ecosystems. Consequently, the ratifying parties left the
development of substantive rules used to guide scientific and economic issues to an
ad hoc and ongoing Working Group. 3 3 This Working Group has met several times,
and through a process of stating positions and discussion, has begun to develop a
more common understanding of the elements that a binding international protocol
on biological diversity should contain. 34 This work builds on a preliminary effort

31

See Convention on Biological Diversity, supra note 23, art. 1, 31 I.L.M. at 823.

32

See PARTICIPATION IN WORLD TREATIES ON THE PROTECTION OF THE ENVIRONMENT, supra note

24, at 268-71.
33

See Convention on Biological Diversity, supra note 23, arts. 28-29, 31 I.L.M. at 834-35.

1

See Governments Start Talks on Biotechnology Safeguards (visited Oct. 23, 1997)

<http//:www.biodiv.org/press/pr7-96.htnl> (releasing information about the meeting of the Working
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made by a group of experts at the first meeting of the conference of parties to the
35
CBD at Nassau, Bahamas, in December 1994.
13. One advantage within the Convention is that by establishing an ongoing
Working Group to grapple with the technological and implementation issues that
must be addressed in a protocol, the many diverse interested parties have an
opportunity to observe the development of international law in this area.36 Though
openness may elicit disparate views on this subject from party and non-party
nations, environmental groups, and members of related industries,3 7 it also helps
those working on the protocol to identify the most critical issues. 3 One hope is that
this debate within the Working Group begins that path to consensus and concludes
with a strong protocol that will not only protect current parties to the Convention,
but will also attract a voluntary commitment to environmental health, technology
security, and cooperation by non-parties.
39

Sheldon Krimsky:
14. I want to say a few words about the substantive body of issues that the
Working Group and others have begun to address. Of particular concern are the
genetically modified products that are emerging and the grassroots opposition to
40
them in many countries.
Group at Aarhus, Denmark); see also A BriefAnalysis ofthe Meeting (visited Oct. 18, 1997)
<http://www.mbnet.mb.ca/linkages/vo9/0948014e.html> (describing some of the political
alignments and negotiations at the Aarhus meeting, including initial attempts to determine what
terms must be defined and agreed upon); Considerationof the Priority ConsensusElements of the
MadridMeeting (visited Oct. 18, 1997) <http//:www.iisd.ca'linkages/voO9/0948000e.html> (noting
progress on identifying a working structure for a protocol at the Working Group meeting in Madrid,
Spain).
M5

See U.N. Expert's Meeting Recommends Protocol on Genetically Modified Organisms, supra

note 25, at 599.
36

See id.

See generally Structureof a FutureProtocol (visited Oct. 18, 1997)
<http://www.mbnet.mb.ca/linkages/vo109/0948009e.html> (outlining the widely varying views on
the shape of a biodiversity protocol).
:17

See Biosafety Working Group Outlines Elements for FutureBiodiversity Convention Protocol,
[1996] 19 Int'l Env't Rep. (BNA) No. 16, at 688 (July 23, 1996).
:8

39

Sheldon Krimsky is a professor in the Department of Urban and Environmental Studies at

Tufts University.
See ConsumersDiffer On Acceptance of Genetically Modified Foods, MILLING & BAKING NEWS,
Mar. 25, 1997, available in LEXIS, News Library, MILBAK File (discussing the results of
international consumer surveys about genetically engineered food and noting particularly strong
opposition in northern Europe); CoalitionSeeks Labeling of Genetically EngineeredCorn, Soybeans;
40
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15. Much of the controversy about biotechnology is focused in Europe, where
some countries refuse to accept certain products, though they are willing to buy and
use others. 41 Considerable European opposition stems from a concern that the
United States is merely using the World Trade Organization 4 2 to pressure nations to
43
accept American products without giving proper credence to European concerns.
Aside from the political misgivings these European countries have about allowing
American products to enter their markets at all, 44 this contentious situation
underscores the need to listen and address the risk management issues that
accompany the advancement and increasing use of biotechnology.
16. In 1992, Dr. Calestous Juma was one of the cosigners and authors of a
45
report by the International Service for National Agricultural Research ("ISNAR").
The report was a first effort to articulate some of the problems in evaluating the
biosafety of this new generation of products. 46 With no viable products on the

Launches Worldwide Boycott, FOOD LABELING NEWS, Oct. 10, 1996, available in LEXIS, Market
Library, IACNWS File (reporting that 300 agricultural, health, and trade groups from 48 countries
threatened a boycott to force major companies to label food products that use transgenic
components).
41

See Julie Wolf, Europe Turns Up Nose at Biotech Food, WALL ST. J., Jan. 2, 1997, at 8

(noting that "only about 5% of foods made with genetically modified raw materials will have to be
labeled as such under a new EU law"); Caroline Southey, EUAgrees Rules For Genetically Engineered
Foods,FIN. TIMES, Dec. 2, 1996, at 20 (noting that the European Union labeling rules provide a
"loophole... [for] oil made from genetically modified soybeans to be marketed without a special
label ...[and for] a mix of genetically engineered and conventional products to be imported without
extra labels").
42

The World Trade Organization is the successor to the General Agreement on Tariffs and

Trade (GATT). See FAQ (visited June 3, 1998) <http://www.wto.org/faqs/faq.html>. The WTO is
an "international agency overseeing the rules of international trade." Id.
See U.S. Formally ProtestsEU Ban on Beef Treated With Hormones, HOUSTON CHRON., May
9, 1996, at 4 (reporting that the U.S. filed formal charges with the World Trade Organization in
hopes of forcing the European Union to repeal its ban on hormone-containing beef).
43

See, e.g., Neil Buckley, Brussels Defends Maize Ruling, FIN.TIMES, Apr. 10, 1997, at 3
(reporting the conflict between the European Commission and the European Parliament over the
importation of genetically modfied corn, most of which would come form the United States); U.S.
Trade Report Singles Out Japan,EU, China for Criticism, L.A. TIMES, Apr. 1, 1997, at D3 (noting
U.S. Trade Representative Charlene Barshefsky's concern that the EU has manifested "pervasive
discrimination against U.S. agriculture exports").
44

45

G.J. PERSLEY ET AL., BIOSAFETY: THE SAFE APPLICATION OF BIOTECHNOLOGY IN AGRICULTURE

AND THE ENVIRONMENT (1992).
46

See id. at 1.

Transgenic Agriculture

4 B.U. J. Sci. & TECH. L. 4

market at the time the report was published, it was mainly a theoretical exercise. 4 7
The report contained some of the central ambiguities and contradictions of our
discourse on biotechnology.
17. One of the greatest tensions in that report, and in reality, is between
power and risk. Some members of the biotechnology debate are caught in this
dilemma by saying that the power of new biotechnology is unique but the risks are
conventional. For example, the ISNAR report quoted a National Research Council
publication that said, "The molecular methods have great power because they
enable scientists to isolate genes and to transfer them across biological barriers." 48
That statement emphasizes the uniqueness of gene splicing, but the authors
diminish its importance by quoting from the same National Research Council
document that says, "Crops modified by molecular and cellular methods should pose
risks no different from those modified by classical genetic methods for similar
traits."4 9 This creates a strange ambiguity. On one hand, it is alleged that we
control this great power because we can cross species barriers, while on the other
hand, we treat this power as if it is no different than traditional hybridization.
18. This false inference is often made because of confusion between precision
and predictability. Recombinant DNA techniques are more accurate, or precise,
than classical techniques for modifying organisms.5 0 Simply because scientists have
higher levels of skill at creating technological applications for the fields of biology
and agriculture does not mean that they necessarily have the insight to foretell, or
predict the consequences of the technology, such as the properties of a living
modified organism. 51 The result is an unfounded leap from understanding
genotypes 52 to thinking we understand phenotypes 53 to believing we can predict

See id. at 5. But see Biotechnology and Genetically Altered Foods: The Future is Now What
Will We Make of It?, ENVTL. NUTRITION, Oct. 1, 1996, at S1, available in LEXIS, News Library,
ASAPII File [hereinafter The Future is Now] (noting that the FDA approved rennet in 1990, the first
biotechnology product produced by trausgenic bacteria).
47

PERSLEY ET AL., supra note 45,

at 7 (quoting the National Research Council Report).

49

Id. at 6.

50

See id. at 3.

51

See id. at 4. Henry I. Miller consistently makes this error in POLICY CONTROVERSY IN

BIOTECHNOLOGY: AN INSIDER'S VIEW (1997).

52

A genotype is "all or part of the genetical constitution of an individual or group." MERRIAM

WEBSTER'S COLLEGIATE DICTIONARY 487 (10th ed. 1994).

53

A phenotype consists of "the visible properties of an organism that are produced by the

interaction of the genotype and the environment." Id. at 872.

Transgenic Agriculture
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ecological impacts. 54 There is no knowledgeable basis for moving from
understanding genotypes to predicting ecological effects. 55 Simply predicting which
genes are in the new organism does not provide a sound foundation for guessing the
likely ecological effects of releasing that organism into the wild. 56 Nor does this
intellectual leap identify the particular types of risks about which we should be
57
concerned.
19. There are two types of risks in this area, which I call first- and secondorder effects. Consider the implications of genetically modifying a plant. A firstorder effect could be the creation of an ecological imbalance that adversely impacts
humans or human systems, such as reducing the nutritional value of the transgenic
plant. 58 Second-order effects are less direct. For example, they might occur when
growing a genetically modified plant that is susceptible to pests and requires large
amounts of a certain herbicide. Over use of the herbicide might cause weed
59

resistance and eventually diminish the herbicide's utility.

Second-order effects

often escape regulatory oversight in the United States. In reality, these two types of
risks, and their effects, may overlap.

See EPA Recommended to Adopt a Process-BasedApproach, BIOTECH. BUS. NEWS, Feb. 25,
1994, available in LEXIS, Market Library, BIOBUS File (stating that recombinant DNA makes

54

possible "novel genetic combinations [which] 'create uncertainties about how the gene will function
and how its products may affect the phenotype and its impact upon the environment and human
health."').
55

See id.

56

See id; see also MAE-WAN Ho, GENETIC ENGINEERING: DREAM OR NIGHTMARE? (1998).

For example, although some scientists suspected that herbicide-resistant crops might cause
environmental problems, the nature of the trouble was not known in 1993. See TransgenicPlants
Pose Minimal Risk, BIOTECH. BUS. NEWS, July 2, 1993, at 17, availablein LEXIS, Market Library,
BIOBUS File. Thus, initial reports suggested that transgenic plants posed little environmental
risk because the herbicide-resistant crops were unlikely to develop the invasive properties of weeds.
See id. Three years later, researchers found an environmental problem: the genetically engineered
herbicide resistance may have spread to nearby weeds through ordinary cross-pollination. See
HerbicideResistance Spreads to Weeds, APPLIED GENETICS NEWS, Mar. 1, 1996, available in 1996 WL
8541653.
57

58

The FDA must grant approval for the sale of a food product if its nutritional value as a
transgenic food is outside of the normal range for the non-transgenic version. See The FutureIs Now,
supra note 47.
59

See HerbicideResistance Spreads to Weeds, supranote 57 (discussing Danish study about
spread of genetically-engineered herbicide tolerance); see generally SHELDON KRIMSKY & ROGER P.
WRUBEL, AGRICULTURAL BIOTECHNOLOGY AND THE ENVIRONMENT: SCIENCE, POLICY, AND SOCIAL
ISSUES (1996).
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20. A high profile example of a transgenic food issue is the bovine growth
hormone used to stimulate milk production in dairy cows. 6 0 This example
demonstrates our preoccupation with first-order effects without a commensurate
concern for second-order effects. In the debate over the bovine growth hormone,
proponents and opponents alike focused on its health effects for human cow-milk
consumers. 6 1 When the mainstream scientific community could not point to direct
human health effects from the hormones, 62 the hormones were permitted for use in
American dairies 63 without any significant investigation of secondary effects on
humans or animals. The necessary regulatory oversight was absent, failing even to
64
insist that the public be informed about hormones through appropriate labeling.
Litigation will be the unfortunate result of this misunderstood and underappreciated risk.
21. The risk assessment protocols that we have in the United States are
woefully inadequate. What we have amounts to a voluntary system for assessing
the risks of transgenic food. Companies that make new food products regulate
themselves by comparing their products against certain guidelines issued by the
Food and Drug Administration ("FDA"). If businesses decide that their genetically
modified products and foods meet the guidelines, then they are free to produce,
65
market, and sell their products without any significant governmental oversight.
The system relies on the corporations that produce genetically modified foods to
identify to the FDA any products that are out of compliance with the most basic and
routine safety regulations. The FDA does not conduct an analysis of every food
product made by transgenic methods. 66 I think this failure to impose stricter

60

See, e.g., Steven Pratt, Growth Hormone for Dairy Cows Draws Concern, CIT. TRTB., Dec. 16,

1993, at 48.
61

See Rogers Worthington, To Dairy Industry,Hormone Top Issue, CHI.TRIB., Jan. 7, 1990, at

21 (reporting that in Wisconsin, the debate had "shifted from health concerns to the consumer's
right to know" and that concerns about animal health and the economic survival of the small diary
farm had fueled the opposition).
62

See International Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 75 (2d Cir. 1996) (Leval, J.,

dissenting) ("Based on its study, the FDA authorized commercial use of rBST on November 5, 1993,
concluding that 'milk and meat from [rBST-treated] cows is safe' for human consumption.").
G3

See id. at 69-70.

Cf The FutureIs Now, supra note 47 ("The FDA... does not require genetically altered
foods to be labeled solely because they are genetically engineered.").
64

65

See id.

66

See Statement of Policy for Regulating Biotechnology Products, 51 Fed. Reg. 23,309, 23,309

(1986); The Future is Now, supranote 47 (stating that the FDA uses a case-by-case approach). The
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scrutiny comes from the initial false inference I mentioned. 67 I believe that the FDA
assumes that when you put foreign genes into food, even if the genes cross species
lines, the new variety is substantially equivalent to the old.6 8 The FDA accepts,
uncritically, the analogy between genetically modified food and hybridization of two
crops in the same family.6 9 Instead, genetic modification is much more like putting a
peanut gene into a tomato than crossing two strains of corn.
22. As important as regulatory oversight of the production phase is, it should
also be of concern that we have no systematic tests for evaluating the allergenicity of
transgenic food products, a first-order effect that should provoke significant
concern.7 0 America does not have a single agency committed to testing for human
allergic reactions to genetically modified food products. 71 Human beings have an
amazingly wide range of tolerance but also a wide range of allergies to plants that
are used as foods. 7 2 My concern is that when we begin mixing proteins across species
73
lines, we could find that people will become allergic to some of the new foods.
4
deadly.
and
Without testing, these effects can be unpredictable
"FDA has determined that plant foods produced through biotechnology present no inherent risk and,
therefore, should be regulated like any other food entering the marketplace," meaning that only
foods that meet certain criteria based on their characteristics, not how they were made, will be
regulated. See also Positionof the American DieteticAssociation: Biotechnology and the Futureof
Food, 95 J. AM. DIETETIC ASS'N 1429, 1431 (1995) [hereinafter Position of the American Dietetic
Association].
67

See supra notes 58-59 and accompanying text.

6S

See Statement of Policy for Regulating Biotechnology Products, 51 Fed. Reg. at 23,312-13.

69

See id.

70

Ignorance of a food's allergic effects is an important first-order concern because, without

testing, it is impossible to tell to which foods people are allergic and what allergic reactions may
result. See Rick Weiss, Report Cites Risk of Allergic Reaction in Brazil Nut Gene-Engineered Soybean,
WASH. POST, Mar. 14, 1996, at A1O; see also Long March of the Tomato, WASH. POST, May 21,
1994, at A22 (reporting on allergy concerns about the Flavr Savr tomato).
See Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. 22,984,
22,985 (1992) (citing the FDA as the primary federal agency for regulating genetically altered food
and the U.S. Department of Agriculture and the Environmental Protection Agency as secondary
agencies).
71

72

See id. at 22,987 ("[G1nly a small fraction of the thousands of proteins in the diet have been

found to be food allergens."). Although approximately 1.5% of U.S. adults and 6% of U.S. infants
have food allergies, most people develop a tolerance to the problematic foods. See Food Allergy:
Number of People With Food Allergies on the Rise, DISEASE WKLY PLUS, Oct. 6, 1997, availablein
1997 WL 13677901.
73

See Statement of Policy: Foods Derived from New Plant Varieties, 57 Fed. Reg. at 22,987

("FDA's principal concern regarding allergenicity is that proteins transferred from one food source to
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23. Another concern is that when plants are genetically modified by mixing
proteins across species lines, some of the transferred proteins will come from
bacterial genes.7 5 That, too, may cause allergic responses. In addition, it may cause
76
new types of antibiotic resistance, a second-order effect.
24. I propose that we need to know the full scope of the effects of transgenic
agriculture before we encourage it. Simply guessing that a transgenic plant or
product will be safe because the unmodified products were genetically safe, perhaps
with minimal human allergenicity, is not an appropriate response to the potential
risks. Today's trend in biotechnology is to treat our current food sources as the feed
stock for a new food industry.7 7 If this view is analogous to the evolution of the
chemical industry, from the use of naturally occurring chemicals to the modern
synthetic chemical production, then there will be an enormous exchange of proteins
across all the food types. 7 Whether this is an expansion that people desire is
79
another question altogether.
25. I recently spoke with a woman who is a member of the National Institute
for Environmental Health Sciences.8 0 She has worked on hormones throughout her
another.., might confer on food from the host plant the allergenic properties of food from the donor
plant."); Long March of the Tomato, supra note 70 (noting that the introduction of new substances
into foods could cause allergic responses in people because the foods need not be specially labeled).
See Weiss, supra note 70 (noting that allergic reactions can range from "a rash to a lifethreatening lung inflammation"); see also Beatrice Trum Hunter, Put Down that Glass of Milk and
Read This:Bovine Growth Hormone May Cause Allergies, HEALTH NEws & REv., Jan. 1, 1995, at 8
(discussing the possible adverse consequences for infants and adults from exposure to the bovine
growth hormone in milk).
74

75

But ef id. (stating that bacteria genes rarely cause allergic reactions when used in

genetically altered food).
76

See The Future is Now, supranote 47 (explaining that pests may develop resistance to the

toxins that were genetically engineered into plants to keep those insects away).
77

See Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. at 22,965.

78

See KRIMScY, supra note 26, at 98-99; see also Jane E. Brody, A Cool Look at Genetically

Altered Foods,N.Y. TIMES, May 19, 1993, at C13 (discussing various naturally occurring proteins
that may be added to food).
See Mary Jane Angelo, Genetically EngineeredPlantPesticides:Recent Developments in the
EPA's Regulation ofBiotechnology, 7 U. FLA. J.L. & PUB.PoLy 257, 288-90 (1996) (discussing
public perceptions of biotechnology in food production); see also Karen Goldman Herman, Comment,
Issues in the Regulation of BioengineereedFood, 7 HIGH TECH. L.J. 107, 111 (1992) (stating that
negative public perception of bioengineered food may lead to tighter regulation).
79
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The National Institute for Environmental Health Sciences is one of the National Institutes

for Health. See NIEHS: Introduction (visited June 4, 1998)
<http://www.niehs.nih.gov/external/intro.htm>. The Institute attempts "to reduce the burden of
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scientific career. When I asked her whether she would drink milk that was produced
with bovine growth hormones, she emphatically said, "No," that she would choose
milk without the hormone every time. Her decision was not based on any hard data,
but rather a visceral feeling about the current state of events, which does not give
individuals an opportunity to choose whether to accept exposure to unknown risks. 8 '
The concern stems from private industry's control of research, development, and risk
assessment of genetically engineered organisms, all without governmental
oversight 8 2 I wonder how much confidence we can have in the data, which are not
generally available to the public and are produced by the companies that own
transgenic products. The question of trust should prompt us to consider whether we
have a sufficient number of disinterested scientists to review these new products
83
independently and to evaluate the industry's tests.
26. If these problems create significant and deep divisions in America, there
is little doubt that we have a long way to go in proving the safety of transgenic
products before the world community will accept them. American industry and
policymakers must be more sensitive to the fact that opposition to American
biotechnology from certain countries may not be based upon a well-defined and
specific endpoint risk.8 4 Rather, international distrust of American biotechnology
stems from a logical reaction to a lack of vital information about the risks and
benefits of genetically modified organisms and plants. The remedy for this distrust
is to provide more information and enough time to understand and evaluate the
data independently.
27. Food security is a pressing issue for many nations. When countries that
face the brunt of food shortages and malnutrition show hesitance toward adopting
the new technologies out of fear that they will jeopardize their fragile indigenous
agricultural systems, the world, and especially the biotechnology producers, needs to
pay close attention. People need sufficient time to understand what is happening to
human illness and dysfunction from environmental causes by understanding the interaction" of
environmental factors, individual susceptibility, and age. Id.
81
See Interim Guidance on the Voluntary Labeling of Milk and Milk Products From Cows That
Have Not Been Treated With Recombinant Bovine Somatotropin, 59 Fed. Reg. 6279, 6279-80
(1994).
82

See Amy Beth Gooen, Consumer Education Needed for Biofoods to Get to Market, FOOD &

DAILY, Jan. 26, 1993, availablein 1993 WL 2792289 ("'Most companies are honest, but
given the current climate of public skepticism, the appearance of impropriety could prevent consumer
acceptance of a new technology,' [Michael Phillips of the U.S. Congress Office of Technology
Assessment] said.").
DRINK

83

See id.

See Scott Kilman, Europe Shifts Stance on Demand Over Genetically Altered Crops, WALL ST.
J., July 25, 1997, at A2 (explaining that European consumers are generally more apprehensive
about genetically altered crops and labeling than Americans).
84

4 B.U. J. Sci. & TECH. L. 4

Transgenic Agriculture

their food supply.8 5 To transform the world's food supply, we will need a much better
sense of the timing that it takes to do good risk assessment and the techniques
required to evaluate whether these products will pose first or second order risks to
the world community.
86

Rufus King:
28. As a lawyer who represents a number of small companies that are trying
to make sense of the regulations that control genetically modified products, I am
often in the position of having to explain the difference between the real and
perceived risks that these products pose. As far as the Convention 7 is concerned,
biological diversity, in the abstract, is something that people simply should support,
just as they should support moderation of global warming or nuclear disarmament.
At a local level, however, I believe that many people in the biotechnology industry
are somewhat dismayed by the pictures of activist groups, such as Greenpeace,
attempting to bar the importation of genetically modified products based on their
concern for biological diversity.8 8 Perhaps these activist groups do not understand
the connections between these products and other pressing social issues.8 9
29. Part of the reason that Americans may be more comfortable than our
European trade partners with the idea of genetic modification is that Americans
have been confronting and debating this issue far longer. A number of cases went
through the federal courts in the United States in the early 1980s90 and attempted
to prevent field studies of these plants because the testing prior to their natural
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See Hunter, supranote 74, at 8 (noting that it takes years to study the incremental effects of

genetically engineered food).
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Rufus King is a partner in the Boston law firm of Testa Hurwitz & Thibeault, LLP.
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See Convention on Biological Diversity, supra note 23, 31 I.L.M. 818.
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See European Commission OKs Gene-Modified Corn, MEALEY'S LITIG. REP.: BIOTECH., Dec. 31,

1996, at 9 (reporting that Greenpeace protesters had chained themselves to a French dock where

modified corn would arrive).
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See, e.g., id. See also Paul B. Thompson, Food Biotechnology's Challenge to CulturalIntegrity

and Individual Consent, HASTINGS CTR. REP., July 17, 1997, at 34, available in 1997 WL 10124572
(reporting that ethical, cultural, and religious concerns have caused much controversy);
GREENPEACE: Legal Action Filed Against U.S. EPA Over its Approval of Genetically Engineered
Plants,M2 PRESSWIRE, Sept. 19, 1997, available in 1997 WL 14463385 (reporting that "green"
groups believe that transgenic crops violate federal environmental, agricultural, and procedural laws
and will cause significant human and environmental harm).
See, e.g., Foundation on Economic Trends v. Heckler, 587 F.Supp 753, 755-57 (D.D.C.
1984), vacated inpart, 756 F.2d 143 (D.C. Cir. 1985).
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release violated the National Environmental Policy Act of 1969. 9 1 As a result of this
litigation, Congress held numerous hearings and debates to begin to understand the
effect of releasing genetically modified organisms and to shape a pattern of
regulation.
30. The American system of regulating biotechnology products is highly
complicated, a virtual alphabet soup of state and federal agencies with overlapping
authority. The FDA is one of the best-known agencies involved in biotechnology
regulation. Under the Federal Food, Drug, and Cosmetic Act, 92 the FDA has
jurisdiction over all new foods and food additives to ensure that the products do not
93
have any harmful qualities and are appropriately labeled.
31. The United States Department of Agriculture ("USDA") has jurisdiction
over plants that have the potential to become harmful, a "pest,"94 in the natural
environment. 95 The USDA carefully controls which companies can conduct field
tests, how they carry out those tests, and how the tests assess for safety.9 6 The
USDA ultimately must grant approval for these products to enter interstate
commerce.97
32. The other major federal agency involved with transgenic agriculture is the
Environmental Protection Agency ("EPA"). The federal Insecticide, Fungicide, and
Rodenticide Act allows the EPA to regulate any product that has a pesticidal effect
and does not come from a naturally occurring food source. 98 This brief description of

42 U.S.C. § 4332 (1994).
92

Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-395 (1994).

See id. §§ 341-350b (prohibiting the sale of unsafe foods and providing for more detailed
regulation on relevant issues such as pesticide residues on food).
93

See id. § 150aa(c) (defining a plant pest as "any living stage of: Any insects, mites,
nematodes, slugs, snails, protozoa, or other invertebrate animals, bacteria, fungi, other parasitic
plants or reproductive parts thereof, viruses, or any organisms similar to or allied with any of the
foregoing, or any infectious substances, which can directly or indirectly injure or cause disease or
damage in any plants or parts thereof, or any processed, manufactured, or other products of
plants").
94

See Plant Pests, 7 U.S.C. §§ 150aa-jj (1994) (describing the USDA's authority to regulate
agriculture and plants generally).
95

96

See id.

97

7 C.F.R. § 330 (1997).

98

See Environmental Pesticide Control Act, 7 U.S.C. §§ 136-136y (1994) (governing the use

and movement of pesticides).
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federal regulation does not even come close to truly capturing the complexity and
interconnectedness of the regulatory oversight.
33. Each state government provides its own additional overlay of regulation
for this industry and its products. Given this convoluted arrangement, I would not
necessarily advocate world-wide adoption of our regulatory scheme for other
countries attempting to address risk management in the context of transgenic
agriculture. What would be helpful however, is some level of international
harmonization of regulation so that interaction between small, private companies
and other countries is both productive and efficient.
Discussion Session
Michael Baram:
34. I think that the most immediate issue is labeling. As a consumer, I want
to know what foods contain, and therefore be able to make an informed choice about
what to eat. But this does not necessarily require government regulation if market
forces are sufficient to make food producers and retailers voluntarily provide the
desired information. For example, food is highly regulated by the Jewish
community. 99 Before the mark signifying that a particular food is certified as
consistent with the Jewish dietary laws, or kashruth, can be placed on the package,
the religious authority must not only inspect the processing plant but also know
every element in the end product. 100 Though there may be nothing inherently
objectionable about genetically modified agricultural products from the perspective
of Jewish dietary laws, the certifying religious authority must be assured that every
component of the food meets that group's standards. Without clear labeling of seeds
and resulting crops, these private groups cannot even begin to make an informed
choice about what to certify. Thus, a niche market exists, and food companies
competing for this market may opt for voluntarily providing the requisite
information. The same can be said for other specialist markets, such as the organic
food and "vegan" markets, and markets comprised of persons who have food
allergies. So I raise the issue of whether market forces will cause private voluntary
initiatives which will meet the call for labeling genetically modified foods, or
whether government labeling and enforcement programs will be needed.
Sheldon Krimsky:

See Beatrice Trum Hunter, More Consumers Ask: Is it Kosher?, CONSUMERS RES. MAG., Apr.
1, 1997, at 10, available in 1997 WL 10128557 (detailing contemporary controversies over kosher
labeling).
99

i00

See Steven Anderson, Kosher Tag Termed Sales Booster, IDAHO Bus. REV., Apr. 6, 1998, at

7A, availablein 1998 WL 9770016 (stating that the kosher food niche market is expanding for a
variety of reasons associated with the perception that kosher food is safer and cleaner).
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35. Going back to a point made earlier, I do not agree that the BSE experience
can entirely account for Europe's objection to genetically modified plants, such as
genetically engineered corn. 101 I believe that the scientific committees in the
European Union were justifiably concerned about the corn's impact. 102 Yes, the corn
was eventually approved, but the independent testing prior to marketing was not
unwarranted. 103
Calestous Juma:
36. I am intrigued by your comment about the gap between public acceptance
and scientific thought. This is quite reminiscent of the nuclear power debates where
science did itself a disservice by staying entrenched and not addressing questions of
public acceptability. Only when science becomes actively engaged in educating the
public will international agreements follow because the many contentious issues are
based on perception and not fact. My point is that though the public is dealing with
biotechnology, it has the nuclear analogy in mind, even if it is not a good analogy.
This reliance on the false analogy is particularly bothersome when the public must
determine whether to trust scientific opinion because nuclear science is not the same
as biological and genetic science.
Michael Baram:
37. I believe the last few comments indicate a widening gap between what
science can establish and what the public perceives. With such a lack of consensus,
how can courts deal with these problems? Being personally predisposed to concern
about managing risk, I want to know what the risks are and how we can most
effectively and reliably manage them based on scientific principles. Perception is
not a rational basis for policy or regulation because it will vary based on dynamic
social and cultural factors within each individual nation. Some countries will
respect scientific rationality while others may give considerable weight to the views
of emotional advocates or self-serving organizations. Without a scientific
foundation, there will be no discipline or structure for appropriate resolution of these
issues.
38. Professor Krimsky recently wrote an excellent paper which illustrates the
indispensability of good science in policymaking. 1 4 In the paper, he discusses how to
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See supra notes 88-89 and accompanying text.
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See European Commission Oks Gene-Modified Corn, supra note 88, at 9.
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See id.; Elizabeth Wise, EU on Verge of Allowing U.S. Corn Imports, USA TODAY, Dec. 18,

1996, at 10B.
IM
See Sheldon Krimsky et al., StandardizedMicrocosms in Microbial Risk Assessment, 45
BIOSCIENCE 590, 592 (1995) (proposing that regulatory agencies, in collaboration with microbial
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assess risk associated with the release of modified organisms to combat
agricultural pests,1 0 5 and carefully scrutinizes the limitations of our current risk
management techniques. 106 Maybe Professor Krimsky could describe for us how
close science is to accurately predicting whether release of a microorganism designed
to kill a particular insect pest could create unintended ecological problems.
Sheldon Krimsky:
39. First, I must say that what I have written does not represent a consensus
of scientific opinion. Depending on individual training and background, a scientist's
perspective on risk and risk management could significantly diverge from others yet
remain respectable within that scientist's own discipline and operating framework.
Even within a single discipline, such as genetic research, scientists may differ on
basic issues, such as the potential for harm. Despite this unsettled scientific
opinion on transgenic risks, there has been progress in risk assessment through the
10 7
use of microcosms.
40. By microcosms, I mean releasing complex and potentially underestimated
microorganisms into the environment in stages and attempting to control risks at
each stage.1 08 Many people believe that this is one of science's riskiest moves, even
riskier than introducing genetically modified plants into the environment. 10 9 The
decision to use microcosms requires a complex understanding of the competitive
advantages and disadvantages of modifying a microorganism and releasing it into
the open environment." 0
41. Risk assessment takes time and money. I predict that the government
will have to support the standardization of microcosms before they can be a truly

ecologists, encourage the standardization of methods and procedures for using microcosms in risk
assessment of genetically engineered microorganisms).
105

See id.

106

See id. at 595.

See id. at 592 (noting that scientists have proposed microcosm studies as an effective means
to predict the ecological effects of genetically engineered microorganisms before initiating field
experiments).
107

108

See generally id.

109

See id. at 591 ("Once released, the microbes may establish and disperse in the environment

becoming nearly impossible to eliminate.").
IM
See Microbial Products of Biotechnology; Proposed Regulation Under the Toxic Substances
Control Act, 59 Fed. Reg. 45,526, 45,526 (1994).
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effective tool."1 Neither the United States nor any other country has anything close
at this time to standardized protocols for assessing the risk before release. 112 My
coauthors and I advocate a canonical approach to the area of microcosm and
microorganism research. 113
42. Without standardization, businesses will continue to avoid developing
and using genetically modified microorganisms to preserve their "all natural"
image.114 Without further data on the risks and benefits of these new
microorganisms, businesses have no reason to be confident in biotechnology or the
public perception of biotechnology.115
Michael Baram:
43. Would it be accurate to say that microcosms are "virtual environments,"
replicating the conditions of the open environment? Do these greenhouses allow
scientists to sufficiently test and predict the interaction of the modified
116
microorganisms in nature?
Sheldon Krimsky:
44. That is a fairly accurate description. To create an effective, realistic
microcosm, scientists take actual soil, plants, and other organisms from the planned
117
It
release site. Because every ecological system is unique, this is a critical step.
would not be enough to use a standard soil environment, or the same plants, in every
118
microcosm because that might not replicate the conditions of the release area.

H]

See Krimsky et al., supra note 104, at 592 (stating microorganism study should be required

for regulatory approval).
1

See id. at 593 (stating that agencies base risk assessment on case-by-case experiments).
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See id. at 597 (recommending regulatory authorities require microcosm data).
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See, e.g., Ice Cream Ben & Jerry's (last modified June 3, 1998) <http:\\www.benjerry.com>

(discussing that, although its dairy supplier has decided to allow the use of rGBH, Ben & Jerry's
remains committed to purchasing an rGBH-free dairy supply).
M

See id. (stating that 96% of people do not want to eat genetically altered foods because of

recent food safety scares).
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See Krimsky et al., supra note 104, at 594 (citing the ecological reality that microorganisms

add to laboratory experiments).
117

See S.A. Bentjen et al., Intact Soil-Core Microcosms for Evaluating the Fate and Ecological

Impact of Release of GeneticallyEngineeredMicroorganisms, 55 APPLIED & ENVTL. MICROBIOLOGY 198,
201 (1989).
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See id.
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The microcosm is important because the effects of releasing the modified
microorganism directly into the environment are simply unknown. 119
45. Technically, scientists take a core soil sample and place it in a
containment frame. After injecting the modified microorganism into the soil
sample, the scientists expose it to the same type of climate and moisture conditions
as are present in the open environment. 120 During this time, the modified
microorganism has a chance to settle, or act as it would outside of the microcosm.
Michael Baram:
46. Is there a quarantine period?
Sheldon Krimsky:
47. While the organism develops in the microcosm, scientists continue to take
measurements. For example, they examine whether the modified microorganism
might overtake the indigenous organisms in a way that would produce an ecological
imbalance. 121 Though there is no distinct quarantine period, the scientists using
this controlled testing methodology would certainly have an opportunity to gauge an
organisms's growth in an environment close to the one that nature provides.
Michael Baram:
48. Do you think this would be the surest way to proceed?
Sheldon Krimsky:
49. This process does assess risk by providing the modified microorganism an
opportunity to behave as it would in nature. If the modified microorganism went
wildly prolific, displacing all of the indigenous organisms, then scientists might
decide that release is inappropriate. Or the microcosm might indicate that the
modified microorganism is selectively disadvantageous to certain indigenous
organisms, raising new considerations before release. I believe that this is a
scientifically viable risk assessment method; nevertheless, before we trust the
results of any one microcosm, we need to systematize the process.
Rufus King:
50. As a hypothetical problem, if microcosm studies fail to detect harmful
side effects of genetically altered crops, the American legal system will not

19

Statement of Policy: Food Derived From New Plant Varieties, 57 Fed. Reg. 22,984, 22,985-

87 (1992); Les Levidow, The Oxford Baculovirus Controversy-Safely Testinig Safety?, 45 BIOSCIENCE
545, 549 (1995).
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necessarily be equipped to deal with the resulting harm. I am thinking of a scenario
in which a single farmer chooses not to grow genetically modified crops because the
local organic food cooperative will not recognize these plants as organic. All of the
farmer's neighbors then plant genetically altered seeds which, in turn, create a group
of pests that are resistant to whatever natural pest controls the local cooperative
accepts. If the neighbors of those who planted these genetically altered plants
suffered loss from these pesticide-resistant pests, they might have a suit in tort for
defective product design or in contract for breach of warranty. Without clear
scientific causation, however, the organic farmer probably will not be able to recover
for pure economic loss unless he can show a preexisting duty.
Calestous Juma:
51. I agree that trade issues always play a role in these environmental
debates. There is always a hope that international agreements dealing with the
environment, such as the Convention, will be able to express a level of consensus on
the trade issues that interact with science and the environment. And, should
consensus ever develop on the trade issues, that will free international efforts to
confront the more difficult scientific issues squarely.

